AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
Aromasin approved in Japan; Pharmacia submits NDA for Eplerenone in hypertension.(Brief Article)
2002 AUG 15 - (NewsRx.com & NewsRx.net) -- Pharmacia Corp. announced that Aromasin (exemestane tablets) 25 mg once daily received approval from Japan's Ministry of Health, Labor and Welfare for the treatment of breast cancer in postmenopausal women. Aromasin was studied in postmenopausal women with advanced or recurrent breast cancer that had progressed following antiestrogen therapy.
"The approval in Japan reinforces the global oncology community's confidence in Aromasin as an important treatment for breast cancer," said Gabe Leung, group vice president, global oncology franchise. "With the drug now approved in 49 countries, including the world's top 2 pharmaceutical markets, Japan and the U.S., Aromasin is an increasing contributor to Pharmacia's global oncology business."
First approved in the United Kingdom ...
- Pfizer Receives European Approval to Market Aromasin(R) for Adjuvant Treatment...
- Press release article from: PR Newswire September 13, 2005 700+ words
Aromasin Now the First and Only Hormonal Breast Cancer Drug Approved...the new early breast cancer indication are...near future. Aromasin has also been...Administration approved Aromasin for advanced breast cancer in post menopausal...
- Pharmacia & Upjohn Launches AROMASIN(R) (exemestane tablets) - A New Breast...
- Press release article from: PR Newswire January 21, 2000 700+ words
...therapy. Today's introduction of AROMASIN closely follows another breast cancer milestone for Pharmacia &...treatment of early node-positive breast cancer. "AROMASIN is the second new breast cancer treatment we've brought to patients...
- Preliminary Data Show Longer Time to Tumor Progression with AROMASIN(R) Versus...
- Press release article from: PR Newswire May 22, 2000 700+ words
...of advanced breast cancer in postmenopausal...women taking AROMASIN(R) (exemestane...comparison." AROMASIN is indicated...of advanced breast cancer in postmenopausal...estrogen. Some breast cancer cells need...estrogen again. AROMASIN interferes...
- New Data On Pfizer's Aromasin and Ellence to Be Presented at San Antonio Breast...
- Press release article from: PR Newswire December 14, 2006 700+ words
...treatment of advanced breast cancer." * Aromasin: Efficacy in the Treatment of Early Breast Cancer Data from the National...hormonal therapy. Aromasin is also indicated...treatment of advanced breast cancer in women with natural...
- FDA Approves Pfizer's Aromasin(R) for Adjuvant Treatment of Early Breast Cancer...
- Press release article from: PR Newswire October 5, 2005 700+ words
...FDA) to market Aromasin(R) (exemestane...positive early breast cancer following two...receptor positive breast cancer who were followed...Patients receiving Aromasin experienced a significant...European Union. Aromasin was approved in...treatment of advanced breast ...
- Breast Cancer Patients Switched to Pfizer's Aromasin Were More Likely to Remain...
- News wire article from: AScribe Health News Service March 10, 2004 700+ words
...Post-menopausal breast cancer patients who switched...from tamoxifen to Aromasin (exemestane tablets...receptor positive breast cancer receive tamoxifen...who switched to Aromasin after two or three...treatment of primary breast cancer. It shows that patients switched ...
- Breast Cancer Patients Switched to Pfizer's Aromasin Were More Likely to Remain...
- News wire article from: Europe Intelligence Wire March 10, 2004 700+ words
...Post-menopausal breast cancer patients who switched...from tamoxifen to Aromasin (exemestane tablets...receptor positive breast cancer receive tamoxifen...who switched to Aromasin after two or three...treatment of primary breast cancer. It shows that patients switched ...
- Breast Cancer Patients Switched to Pfizer's AROMASIN Were More Likely to Remain...
- Press release article from: PR Newswire March 10, 2004 700+ words
...Post-menopausal breast cancer patients who switched...from tamoxifen to AROMASIN(R) (exemestane...receptor positive breast cancer receive tamoxifen...who switched to AROMASIN after two or three...treatment of primary breast cancer. It shows that patients switched to ...
- Pfizer receives European approval to market Aromasin for adjuvant treatment of...
- News wire article from: Asia Africa Intelligence Wire September 13, 2005 700+ words
...approval to market Aromasin (exemestane tablets...positive invasive early breast cancer following two-to...postmenopausal women. Aromasin is a hormonal therapy...receptor positive breast cancer who were followed for...Patients receiving Aromasin experienced a significant...
- Breast cancer patients switched to Aromasin more likely to remain cancer free.
- Newspaper article from: Biotech Business Week April 5, 2004 700+ words
...Post-menopausal breast cancer patients who switched...from tamoxifen to Aromasin (exemestane tablets...receptor positive breast cancer receive tamoxifen...who switched to Aromasin after 2 or 3 years...treatment of primary breast cancer. It shows that patients switched ...
Source: HighBeam Research, Aromasin approved in Japan; Pharmacia submits NDA for Eplerenone in...